Navigation Links
Ausio Pharmaceuticals to Present at Bio(R) 2009
Date:5/14/2009

Initial results from preclinical and Phase 1 safety studies, and plans for Phase 2 studies for menopausal symptoms and benign prostatic hyperplasia (BPH) are to be presented

CINCINNATI, May 14 /PRNewswire/ -- Ausio Pharmaceuticals, LLC, a biotechnology development company focused on medicines for an aging global population, will lead off the Bio(R) Business Forum in a presentation on May 19, 2009 at 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, a pharmaceutical formulation of the soy metabolite S-equol. AUS-131 is expected to provide soy health benefits by consistently delivering therapeutically appropriate levels of S-equol, validated in clinical trial programs. Ausio has successfully completed two Phase 1 clinical trials for AUS-131, and Phase 2 studies are scheduled for treatment of menopausal symptoms and BPH.

AUS-131 Preclinical and Phase 1 Clinical Results

AUS-131 is pure, synthetic S-equol, a soy metabolite, and acts as a nonsteroidal, nonhormonal, selective estrogen receptor beta (ER beta) agonist. The safety profile of AUS-131 in FDA-required preclinical studies was excellent, and AUS-131 has demonstrated positive effects in rodent models of menopausal hot flashes and BPH, supporting its promise for the treatment of these conditions in humans. In Phase 1 trials, AUS-131 demonstrated a favorable safety and pharmacokinetic profile, with no significant drug-related adverse events at doses several-fold higher than the expected therapeutic range.

Phase 2 clinical trials to assess the efficacy of AUS-131 for relief of menopausal symptoms and BPH are on schedule to begin September 2009. The expected completion date for the Phase 2 clinical trials is Q2 2010.

About AUS-131

AUS-131 is pure, synthetic S-equol, a potent metabolite of the soy isoflavone, daidzein, which is produced in only a subset of individuals. AUS-131 is a first-in-class, nonsteroidal, nonhormonal, selective ER beta agonist that has the potential to provide therapeutic benefits with an excellent safety profile compared to estrogen. AUS-131 is being evaluated for a wide range of indications, including menopausal symptoms, benign prostatic hyperplasia, osteoporosis, and topical applications.

About Ausio (www.ausiopharma.com)

Ausio Pharmaceuticals, LLC is a global biotechnology development company committed to cultivating key partnerships with the goal of advancing medicines for an aging population. Ausio was founded in 2006 based on technologies licensed from the Australian Health and Nutrition Association Ltd, NSW, Australia and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio and has garnered strong patent position for its lead compound, AUS-131.


'/>"/>
SOURCE Ausio Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):